Nonconventional diabetes-related care strategies for patients with chronic kidney disease: A scoping review of the literature

Kristin K Clemens1,2,3,4,5, Vinusha Kalatharan3, Bridget L Ryan2,6 and Sonja Reichert4,6

Abstract

Background: Patients with diabetes and chronic kidney disease (CKD) are at high risk of diabetes-related complications. Diabetes care can support these individuals, but outpatient clinic appointments can be difficult to attend, given their already high burden of multimorbidity.

Methods: We systematically searched the medical and grey literature for studies that evaluated the effect of non-conventional diabetes care strategies on diabetes-related outcomes in adults with stages 2–5 CKD or using dialysis (end of search December 30, 2017). We included both randomized-controlled trials and observational studies. Study selection and data extraction were completed by two independent reviewers. Diabetes-related outcomes included glycemic, blood pressure, and lipid control, along with microvascular complications, macrovascular complications, and death.

Results: After screening 2177 relevant citations, we identified 34 studies which met inclusion. The majority were observational studies. Studies were frequently small, single-centered, and excluded patients with more advanced CKD. Non-conventional diabetes care strategies included community-based care, unique self-management and education programs, nurse-led care clinics, dialysis-based diabetes programs, telemedicine, and interdisciplinary care clinics. Programs were most often developed by study investigators. Although there were limitations to several of the included studies, programs were described to have modest effects on physiologic outcomes, and in some cases, diabetes-related complications and death.

Conclusions: Nonconventional diabetes-related care might be helpful to patients with CKD. Prior to developing and implementing programs, however, it will be important to study them more rigorously, understand their acceptability to patients, and evaluate their costs and feasibility in a real-world setting.

Keywords
Diabetes, delivery of health care, renal insufficiency, chronic
Introduction

The prevalence of multimorbidity is increasing among patients with diabetes. It is estimated that most adults with diabetes now live with at least one comorbid chronic disease, and as many as 40% have three or more other medical conditions.\(^1\)–\(^3\)

Patients who live with diabetes and chronic kidney disease (CKD) are an especially vulnerable population. Compared with those without kidney disease, they struggle with dysglycemia and are at increased risk of microvascular disease, macrovascular disease, and even death.\(^4\)–\(^6\) Glycemic management, diabetes education, dietary counseling, and screening for diabetes-related complications can be helpful to these individuals.\(^7\)\(^,\)\(^8\)

Traditionally, diabetes-related care is provided to patients at separate outpatient clinic appointments with physicians and allied health professionals (i.e. certified diabetes educators, dieticians) every 3–6 months. For patients with CKD and diabetes who live with many other medical comorbidities, these additional clinic appointments can be difficult to attend and can add to an already high burden of health care. At busy outpatient clinic appointments, healthcare providers can also struggle to fully address their complex needs.\(^1\)

Nonconventional diabetes care strategies (i.e. diabetes care that is not delivered at traditional outpatient clinic appointments with physicians, diabetes educators, or dieticians), might better support these vulnerable individuals. To our knowledge, there has been no previous effort to systematically identify and describe the effect of these strategies on diabetes-related outcomes in patients with CKD. A thorough review of the literature is important, as we look toward new alternatives to manage complex patients in a patient-centered manner.

Scoping reviews of the literature can help investigators to examine the extent, range, and nature of available evidence.\(^5\)\(^,\)\(^7\) We conducted a scoping review of studies which evaluated the effect of nonconventional diabetes care strategies on diabetes-related outcomes in adults aged \(\geq 18\) years with diabetes and CKD. Our primary aims were to: (1) understand the breadth of nonconventional diabetes-related care strategies and (2) ascertain how these programs were developed and implemented. Our secondary aim was to determine the effect of these programs on diabetes-related outcomes (i.e. metabolic control (glycemic control, blood pressure, and lipid control), microvascular complications, macrovascular complications, and death).

Methods

Design

We conducted our review using the methods suggested by Arksey, Levac, and Tricco (PRISMA-ScR).\(^10\)\(^,\)\(^11\) Our processes were guided by an internal, unpublished protocol.

Patients

We included studies of adults aged \(\geq 18\) years with CKD and diabetes (type 1 or 2). We defined CKD as stages 2–5 disease (i.e. an estimated glomerular filtration rate (eGFR) \(< 90 \text{ ml/min/1.73 m}^2\) ), the presence of micro or macroalbuminuria, receipt of dialysis, or an investigator diagnosis of CKD.

Diabetes care strategies

We defined nonconventional diabetes care strategies as those where diabetes-related care was provided outside of a traditional outpatient clinic appointment with a physician, diabetes educator, or dietician. Diabetes-related care was defined as the management of glycemia, blood pressure, and lipids; screening for related complications (i.e. microvascular or macrovascular disease); self-management support and education.

Control

Included studies could either have or not have a control group.

Outcomes

Diabetes-related outcomes included physiological outcomes (glycemic, lipid, blood pressure control), microvascular outcomes (retinopathy or blindness, decline in kidney function or progression to renal replacement therapy, neuropathy, gastroparesis, erectile dysfunction, autonomic dysfunction), macrovascular outcomes (myocardial infarction, heart failure, stroke, amputation, ulcers), and death.

Study design

We included both randomized-controlled trials (RCTs) and non-randomized studies (e.g. cohort, case-control, pre- and post-intervention studies).

Identification of studies

We first consulted an experienced health sciences librarian (BD) to develop a comprehensive search strategy. This strategy included a combination of key words and Medical Subject Heading (MeSH) terms that were consistent with our research aims and study population (Table 1 of the Online Supplementary Material). We validated our final search strategy through the retrieval of a key set of previously identified relevant articles.

We next searched electronic databases including MEDLINE, EMBASE, CINAHL, Cochrane Library, Scopus, BIOSIS, and Web of Science for relevant citations published until October 6, 2017 (no start date). We then reviewed the reference lists of all included studies and used the Related Articles feature in PubMed to identify...
| Author            | Country   | Design        | Inclusion                                                                 | # with DM and CKD | Program                                                                                                           | Duration of program | Control                                                                 |
|-------------------|-----------|---------------|---------------------------------------------------------------------------|-------------------|-------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------------------------------------|
| Tobe et al. 12    | Canada    | RCT           | 18+; First Nations, DM2, HTN. Subgroup with DM2 and CKD.                   | 34 (17 intervention) | Reserve clinic visit with home care nurse at 6 weeks, then every 3 months. Stopped BP meds and started Irbesartan (dose titrated as per protocol with specialist support). | 1 year              | Home care nurse visits, but if BP uncontrolled, follow-up appointment set with primary care physician. Letter with treatment recommendations sent. |
| Senior et al. 13  | Canada    | P. cohort     | 17+; DM, HTN, or albuminuria. Subgroup with DM and CKD.                   | 216               | Local clinic visits with allied health professional. Education, BP, cholesterol, and glycemic support. Meds adjusted under protocol with specialist support. | Mean 8.8 months     | None                                                                   |
| Tan et al. 14     | New Zealand | P. cohort    | 40–75, Maori and Pacific natives, DM2, HTN, creatinine 130–300 μmol/l, and >0.5 g proteinuria, previously studied as part of DEFEND study. | 65 (33 intervention) | Community clinic visit with health-care assistant every month. BP management, transport to hospital for other appointments. | 11–21 months        | Usual care                                                             |
| Janmariyapon et al. 15 | Thailand | Cluster RCT  | 18–70, stages 3 and 4 CKD, DM, or HTN. Subgroup with CKD and DM.         | 237 (129 intervention) | Home visits with multidisciplinary care team (health-care officer, village volunteer, family) at 1 month then every 3 months. Education, medication adjustment, and self-management support. | 2 years             | Usual care with group-based educational program at district hospital |
| Tan et al. 16     | New Zealand | P. cohort    | 18–65, Pasifika natives, DM2, ACR >40 on 2/3 samples, eGFR >40 ml/min/1.73 m², life expectancy 2 years. | 43                | Community clinic or home visit with nurse every 2–6 weeks. BP medication adjustment by protocol with support of specialist. Adherence support, education, and comprehensive regular medical review by diabetologist or GP for patients with complex medical history. | 2 years             | None                                                                   |
| Walker et al. 17  | New Zealand | P. cohort    | 18+; DM2 (A1c > 8%), BP > 140/80, ACR > 30 mg/mmol on three occasions separated by 1 week. | 52                | CKD nurse practitioner offered care in family practice clinics every 2 weeks × 12 weeks. Tailored education and care plans, self-management, and education materials. Support for transport to appointments. | 1 year              | NR                                                                     |
| Thomas et al. 18  | United Kingdom | Pre and post | Mild to moderate CKD. Subgroup with DM and CKD.                            | NR (13 GP practices) | CKD care bundle implemented in GP practices, supported by renal nurse. Treat to target BP, self-management, and education (DVD, written information, group sessions). | NR                  | Usual care                                                             |
| Sevick et al. 19  | United States | RCT           | Self-referred, community dwelling adults, DM2, 18+ years. Subgroup with DM and CKD. | 32 (16 intervention) | Group counseling weekly to monthly, glucose meter use training, provision of pedometer, and PalmOne Tungsten/E2 (personal device assistant) to support dietary self-monitoring. | 6 months            | Glucose meter training, provision of pedometer, group seminars, lay diabetes magazine, and monthly contact with study team. |
| Pagels et al. 20   | Sweden     | Pre and post  | CKD with eGFR > 30 ml/min/1.73 m².                                        | 58                | Group sessions every semester for three consecutive days. Self-management education, exercise, problem-solving skills, medication adjustment, and goal setting. | Mean 4 months       | None                                                                   |
| Thomas and Brya 21 | United Kingdom | P. cohort    | 18+; DM at risk of kidney disease, ACR > 2.5 mg/mmol men or >3.5 in women. | 176 (116 intervention) | Self-management package inclusive of written materials, DVD, and self-monitoring diary.                        | NR                  | Usual care                                                             |
| Kazawa et al. 22   | Japan      | P. cohort     | 20–74, DM2, eGFR 15–59 ml/min/1.73 m², attending hospital clinics in Japan. | 62 (31 in intervention) | Nurse educator face-to-face interview every 2 weeks in home or research center followed by monthly phone calls. Education on diet, drug therapy, and exercise/weight balance, medication adherence, self-management. | 1 year              | Usual care                                                             |

(continued)
| Author                  | Country     | Design          | Inclusion                                                                 | # with DM and CKD | Program                                                                                                                                  | Duration of program | Control                  |
|------------------------|-------------|-----------------|---------------------------------------------------------------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------|--------------------------|
| Trocha et al.          | Germany     | P. cohort       | DM1 with HTN, retinopathy, >500 mg proteinuria, creatinine <26.5 mg/dl.    | 91 (45 intervention) | BP self-management sessions with allied health professionals every week to 4 months. Education, self-monitoring, and self-adjustment of BP medications. | Up to 10 years (mean 124 months) | Usual care               |
| Williams et al.         | Australia   | RCT             | 18-45, DM (type 1 or 2), eGFR < 60 ml/min/1.73 m² or ACR > 2 in men and >3.5 in women, HTN, comprehend English, mentally competent. | 75 (39 intervention) | Renal nurse visits every 2 weeks for medication self-management. Motivational interviewing, medication review, DVD, and self-monitoring BP. | 3 months | Usual care               |
| Van Zuillen et al.      | Amsterdam   | RCT             | Creatinine clearance 20–70 ml/min. Subgroup with DM and CKD.               | 48 (25 intervention) | Addition of nurse practitioner to nephrologist care in outpatient clinic. Promoted healthy lifestyle, self-management support, treat to target BP, and medication adherence. | NR                  | Usual care               |
| Woodward et al.         | United States | P. cohort       | DM2, HTN on >1 BP medication, SBP > 140 mmHg, DBP > 85 mmHg, Subgroup with CKD and DM. | 41               | Clinic appointment with nurse. Education, written materials, treat to target BP, lifestyle advice, and risk factor management. Letter back to the GP to make treatment changes if needed. | 2 years | None                     |
| Garcia-Garcia et al.    | Mexico      | Pre and post    | Patients referred to CKD clinic. CKD stages 3 and 4, at least one follow-up visit. | 228              | Multidisciplinary (nurse, dietician, social worker, physician) CKD clinic visit every 1–3 months. Addressed glycemic control, BP, CKD, CVD risk reduction, anemia, mineral metabolism, medication adherence, and social and economic support. Recommendations about diet and exercise. | NR                  | None                     |
| Leung et al.            | Hong Kong   | P. cohort       | 30–80, Chinese, DM2, albuminuria, creatinine 150–400, no evidence of rapid progression of renal disease. | 160 (80 intervention) | Structured diabetes specialist/pharmacist clinic visit. Saw diabetes doc every 3–4 months with pharmacist visits half-way between clinic visits. Treat to target BP, A1c, and LDL, self-management support, medication adherence, regular lab monitoring, | 2 years | Usual care               |
| Hitomi et al.           | Japan       | P. cohort       | CKD on hemodialysis.                                                      | 32 (17 intervention) | Multidisciplinary visit with physician, dietician, pharmacist, and nurses. Education, self-management support, medication adjustment, and foot care. | NR                  | Dietician only           |
| Bayliss et al.          | United States | P. cohort       | Adult, referred for nephrology care by GP, eGFR 30–59, and comorbid diabetes and/or hypertension. Subgroup with DM and CKD. | 878 (114 intervention) | Multidisciplinary (docs, pharmacists, diabetes educator, dietician, social worker, and nurse) CKD clinic visits every 1–6 months with remote support if needed. Education, self-management support, medication adjustment, depression screening, and dietary assessment. Weekly team meetings to review all patients. | Mean 1.95 years | Shared care between GP and nephrologist |
| Rayner et al.           | United Kingdom | Pre and post | <65, DM, eGFR < 50 ml/min/1.73 m² with decline over time, not receiving RRT or attending pre-dialysis specialty clinic. | 1002              | Weekly database review to identify patients with deteriorating eGFR. Specialist diabetes-kidney clinic visits offered every 2–4 months until home BP was controlled or eGFR decline slowed. Education, BP management, diet and self-management support, and smoking cessation. | NR                  | Usual care               |

(continued)
| Author          | Country        | Design  | Inclusion                                                                                                                                  | # with DM and CKD | Program                                                                                                                                  | Duration of program | Control          |
|-----------------|----------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------|
| Fogelfeld et al.| United States  | RCT     | 18–70, DM2, CKD stages 3 and 4, albuminuria, and micro or macrovascular complications, normal cognitive function, fasting or random glucose < 400mg/dl. | 120 (60 intervention) | Multidisciplinary clinic visit (endocrinologist, nephrologist, diabetes educator, nurse practitioner) every 1 month for 6 months followed by every 2 months for 18 months. Additional follow-up visits if needed. Treat to target BP, A1c, and lipids. | 2 years             | Usual care       |
| Luciano Ede et al. | Brazil       | P. cohort | CKD referred to clinic, followed for 3 months. Subgroup with CKD and DM.                                                              | 368               | Multidisciplinary clinic visit (docs, social worker, nutritionist, nurse, and psychologist) every month. Dietary support, risk factor management, BP control, medication adjustment, glycemic control, smoking cessation, and motivation to adopt lifestyle change. | 1 year              | None             |
| Glover et al.   | United Kingdom| Pre and post | DM and eGFR < 60 ml/min/1.73 m², or rate of decline > 5 ml/min/1.73 m² per year.                                                          | 182               | Diabetic nephropathy clinic with kidney and diabetes specialist nurse, nephrologist, and dietitians. Risk factor management as guided by clinical practice guidelines. | NR                 | Usual care       |
| Lipscombe et al. | Canada       | Cohort  | DM, part of PD program.                                                                                                                  | 132               | Chiropodist available during weekly PD clinics. Foot assessment and education. If wound care required, referred to another chiropody clinic (care provided on site later in study). | 3 years             | None             |
| Low et al.      | Singapore     | Case-control | DM, CKD stages 3 and 4, referred to diabetes-kidney clinic.                                                                              | 837 (418 intervention) | Diabetes-kidney clinic. Patients had combined assessments with nephrologists, endocrinologists, and allied health. Provided glycemic, BP, and lipid control. | Median 3 years      | Usual care       |
| Telemedicine    | United States  | RCT     | 18–, eGFR < 60ml/min/1.73 m², with clinic visit. Subgroup with CKD and DM.                                                              | 447 (191 intervention) | Remote interdisciplinary CKD care via telehealth device every 30 days. In-home training, health literacy, and lifestyle counseling. Management of BP, volume status, proteinuria, DM, mood, lipids, self-management support, and education. In-person clinic visits as needed. | 1 year             | Usual care with educational class |
| Joubert et al.  | France        | Pre and post | 18–80, DM, chronic HD.                                                                                                                   | 15                | Self-monitoring of blood sugar three to six times per day followed by blinded CGM 5 days every 2 weeks. Data sent to a single diabetes expert and recommendations sent back to nephrologist. | 12 weeks            | Usual care       |
| Kepenekian et al. | France       | P. cohort | 18–83, DM2 on insulin, HD for >3 months, A1c >6.5%.                                                                                       | 28                | CGM with insulin titration by remote physician based upon algorithm.                                                                     | 3 months            | None             |
| Dialysis-based diabetes care program Prentice et al. | Canada   | P. cohort | 19–, DM, HD.                                                                                                                               | 57                | Baseline foot assessment with HD nurse with risk stratification and education. Follow-up monthly for those at high risk and annually for low risk. Education and foot care kit provided to those at high risk. | 15 months           | None             |
| McMurray and McDougald | United States  | P. cohort | DM, part of HD program.                                                                                                                   | 83 (45 intervention) | Foot assessment with diabetes care manager with risk stratification. Foot checks quarterly (more frequently if existing foot problem), education, motivational support, and referral system. | 2 years             | Usual care the first year then foot program the subsequent year. |
| Author | Country   | Design   | Indusion                                                                 | # with DM and CKD | Program                                                                                     | Duration of program | Control                                                                 |
|--------|-----------|----------|--------------------------------------------------------------------------|-------------------|--------------------------------------------------------------------------------------------|---------------------|-------------------------------------------------------------------------|
| Neil et al. | United States | P. cohort | 18+, DM, ESRD on HD.                                                     | 32 (13 intervention) | Foot assessment with HD nurse along with individual education, provision of shoes and inserts. | 6 months            | Usual care on alternate dialysis days                                   |
| McMurray et al. | United States | RCT | DM on PD or HD.                                                          | 83 (45 intervention) | DM care manager provided self-management education, motivational coaching, nutrition counselling, BP, lipid and glycemic monitoring, foot checks, screening reminders. Informed physician of need for medication changes. Multidisciplinary diabetes advisory committee provided program oversight quarterly. | 1 year              | Usual care on alternate dialysis days                                   |
| Cappy et al. | United States | P. cohort | HD. Subgroup with DM and CKD.                                             | 8*                | Progressive, self-paced exercise (cycling before or during HD or walking on a treadmill before HD). Option of stretching or lightweight during HD. | 1 year              | None                                                                    |
| Marn Pernat et al. | United States | Pre and post | 18+, DM, initiated HD with at least 13 dialysis sessions.                | 35,513 pre (25,779 post) | Monthly interdialytic foot evaluations. Education, foot assessment, organized wound care, and referral to podiatrist/orthopedic clinic if needed. | NR                  | None                                                                    |

DM: diabetes mellitus; CKD: chronic kidney disease; RCT: randomized controlled trial; HTN: hypertension; BP: blood pressure; P. cohort: prospective cohort; ACR: albumin to creatinine ratio; A1c: hemoglobin A1c; eGFR: estimated glomerular filtration rate; GP: general practitioner; NR: not reported; SBP: systolic blood pressure; DBP: diastolic blood pressure; CVD: cardiovascular disease; LDL: low-density lipoprotein; RRT: renal replacement therapy; PD: peritoneal dialysis; CGM: continuous glucose monitoring; HD: hemodialysis; ESRD: end-stage renal disease.

*Only a subgroup of the study population had CKD and DM.
additional citations. Further, using similar search terms (e.g. nontraditional, diabetes), we searched Google for relevant citations up to December 30, 2017. We completed each search strategy in Google within a single browsing session.

Two reviewers (K.K.C and V.K) independently screened the titles and abstracts of all identified citations against selection criteria and categorized them as include, exclude, or uncertain. We decided a priori to include studies where only a subgroup of patients had both CKD and diabetes, if at least one diabetes-related outcome was reported for the subgroup. If multiple studies reported outcomes for a similar group of patients (e.g. if studies published both short- and long-term outcomes in separate papers for one patient group), we included the longer term study. We excluded studies not written in English, case reports, case series, clinical practice guidelines, reviews, and commentaries. We pilot tested the first 10 citations for consistency and clarity of our selection criteria.

We then retrieved full text articles for those studies that we deemed to include, as well as those we were uncertain about including. All full text articles were reviewed against our selection criteria. Reviewers communicated regularly through the study selection process. If there were discrepancies about whether to include a study, we resolved them by consensus. If no resolution could be attained, a third party resolved the discrepancies (S.M.R). A flow diagram of study inclusion and exclusion is detailed in Figure 1 of the Online Supplementary Material.

**Charting and summarizing the data**

Reviewers used standard forms to abstract the characteristics of all included studies (design, country, publication year), along with their population, intervention, outcomes, and relevant results. Given the heterogeneity of included studies, we presented our results descriptively.

Reviewers completed their charting independently. We pilot tested the first 10 articles to ensure that our data abstraction was consistent and made necessary changes prior to abstracting the remaining articles.

**Results**

Of the 2177 unique citations identified in our literature search, 34 studies met inclusion.12–45 The characteristics of included studies are noted in Table 1, and study outcomes and results are reported in Table 2.

| Country | Year | Study Design | Sample Size | Intervention | Outcomes |
|---------|------|--------------|-------------|--------------|----------|
| Brazil  | 2018 | Observational | 100 patients | Dietary advice | Diabetes control |
| Canada  | 2017 | Randomized controlled trial | 50 patients | Exercise program | Blood pressure |
| France  | 2016 | Cluster randomized controlled trial | 100 patients | Education program | Glycemic control |
| Germany | 2015 | Cohort study | 200 patients | Telemedicine | Heart disease outcomes |
| Hong Kong | 2014 | Case series | 50 patients | Self-management support | Depression outcomes |
| Japan   | 2013 | Pilot study | 20 patients | Group counseling | Health-related quality of life |
| Mexico  | 2012 | Randomized controlled trial | 100 patients | Medication management | Hospital readmission |
| Netherlands | 2011 | Observational | 500 patients | Nephrology consultation | Urea nitrogen |
| New Zealand | 2010 | Randomized controlled trial | 100 patients | Diabetes education | Hemoglobin A1c |
| Singapore | 2009 | Cohort study | 300 patients | Cognitive-behavioral therapy | Hospitalization rates |
| Sweden  | 2008 | Pilot study | 20 patients | Nursing care | Mortality outcomes |
| Thailand | 2007 | Randomized controlled trial | 100 patients | Exercise and nutrition | Diabetes control |

**Self-management support/education**

Nonconventional diabetes self-management support and education programs aimed to help participants adopt healthier lifestyles and self-manage their disease and treatments. However, rather than delivering self-management support traditionally (i.e. at an outpatient education appointment), studies evaluated the effect of printed materials and videos, group counseling, and devices (e.g. Palm Pilots) on patient outcomes. Self-management support programs were administered by allied health professionals, and contact was offered to participants up to once weekly. Most of the programs aimed to improve glycemic control or...
Table 2. Study outcomes and results.

| Study outcomes | Glycemia | Cholesterol | BP | Renal | Retinopathy | Ulcers/Amputation | CVD | Death | Results |
|----------------|----------|-------------|----|-------|-------------|------------------|-----|-------|---------|
| Community-based care |          |             |    |       |             |                  |     |       |         |
| Tobe et al.12 | x        |             |    |       |             |                  |     |       | Not all outcomes reported in CKD/DM group. Some with CKD/DM and existing overt nephropathy had regression to microalbuminuria, but regression to normoalbuminuria did not occur. |
| Senior et al.13 | x        |             |    |       |             |                  |     |       | No change in eGFR and creatinine. Significant reduction in Alc, BP, LDL, and cholesterol in stages 2 and 3 CKD. Significant reduction in SBP for stage 2 CKD. |
| Tan et al.14 | x        |             |    |       |             |                  |     |       | Significant improvement in SBP at 1 year, but no difference over long term. No change in eGFR and albuminuria in 1 year. No change in Alc, cholesterol, CV outcomes, and death. |
| Jiamjariyapon et al.15 | x        |             |    |       |             |                  |     |       | Not all outcomes reported in CKD/DM subgroup. In CKD/DM, significantly lower Alc in intervention group (7.3 vs. 7.9%). |
| Tan et al.16 | x        | x          |    |       |             |                  |     |       | Proportion who reached BP 125/85 doubled over follow-up. Higher proportion had urinary ACR < 30 mg/mmol (19 vs. 33%). Significant reduction in Alc (81 mmol/mol to 71), SBP (137 to 126 mmHg), DBP (84 to 74 mmHg), eGFR (68 to 57 ml/min/1.73 m²), and ACR (126 to 51 mg/mmol). |
| Thomas et al.18 | x        |             |    |       |             |                  |     |       | After intervention, slightly higher proportion met BP targets (48 pre- vs. 49.2 post-intervention). |
| Self-management/education |          |             |    |       |             |                  |     |       |         |
| Sevick et al.19 | x        |             |    |       |             |                  |     |       | Not all outcomes reported in CKD/DM group. No difference in Alc or glucose between intervention and control. |
| Pagels et al.20 | x        |             |    |       |             |                  |     |       | Significant improvement in Alc (7.1 to 6.6%), % of patients with target SBP < 130 mmHg (25 to 45%), and % of patients with target DBP < 80 mmHg (49 to 59%). No change in eGFR and albuminuria. |
| Thomas and Bryar21 | x        |             |    |       |             |                  |     |       | No statistically significant difference in BP and Alc between groups. |
| Kazawa et al.22 | x        |             |    |       |             |                  |     |       | At 24 months, kidney function maintained in intervention but deteriorated in control. No patient started dialysis in intervention (2 in control). Alc significantly declined at 6 months and remained stable thereafter in controls; slight decline in Alc was observed in intervention. No difference in BP and HDL between groups. |
| Trocha et al.23 | x        | x          |    |       |             |                  |     |       | At the end of follow-up, SBP significantly lower in intervention than controls (−4/−6 vs. 5/0.3 mmHg). BP reduced in intervention group and increased in control group. Annual rate of eGFR decline lower in intervention vs. control; 7 (16%) intervention vs. 22 (48%) control died, 11 (24%) intervention vs. 18 (39%) control started HD, 3 (7%) intervention versus 9 (20%) control amputation, and 5 (11%) intervention versus 10 (22%) control new blindness. |
| Williams et al.44 | x        |             |    |       |             |                  |     |       | At 9 months, reduction in BP in intervention and control group with no significant difference between groups. |
| Nurse-led clinic |          |             |    |       |             |                  |     |       |         |
| Van Züllen17 | x        |             |    |       |             |                  |     |       | Not all outcomes reported in CKD/DM. No significant difference in Alc between groups. ACR declined over 12 months (−6.75 mmol/month). Significant reduction in creatinine clearance (−0.3 ml/min/1.73 m²), BP (150/92 vs. 132/76 mmHg), cholesterol (5.25 vs. 4.6 mmol/l), and Alc (8.75 vs. 7.55%) over study duration. |
| Walker et al.17 | x        |             |    |       |             |                  |     |       | Not all outcomes reported in CKD/DM. Significant improvement in SBP (178 to 150 mmHg), DBP (88 to 76 mmHg), and Alc (8.7 to 8.1%). Lower percentage of patients with microalbuminuria (47 vs. 28%). |
| Woodward et al.25 | x        | x          |    |       |             |                  |     |       | (continued) |
| Glycemia | Cholesterol | BP | Renal | Retinopathy | Ulcers/amputation | CVD | Death | Results |
|----------|-------------|----|-------|-------------|-------------------|-----|-------|---------|
| **Interdisciplinary care clinic**<br>Garcia-Garcia et al.26 | x | x | x | x | | | | Significant reduction in fasting glucose (149 to 130 mg/dl), A1c (8.5 to 7.8%) after intervention. Percentage of patients reaching target glucose (<130 mg/dl) improved from 54% to 68%. eGFR declined over time (31 to 28 ml/min/1.73 m²). |
| Leung et al.27 | x | | x | | | | | Intervention had lower SBP (140 vs. 148 mmHg), DBP (68 vs. 72 mmHg), creatinine (4 vs. 5 μmol/l), LDL (2 vs. 3 mmol/l), rate of creatinine change (3382 μmol/l/year), rate of ESRD 13.5 vs. 24 per 100 PYs, and rate of death 4.3 vs. 14.8 per 100 PYs compared to usual care. |
| Hitomi et al.28 | | x | | x | | | | No difference in BP or albuminuria before HD. CV events in intervention 29% vs. controls 53%. No deaths in intervention and 20% in control. |
| Bayliss et al.29 | x | x | x | x | | | | Not all outcomes reported in CKD/DM. No difference in A1c between groups. Significantly lower rate of eGFR decline (−5.2 vs. 1.1 ml/min/1.73 m²) after intervention, fewer started RRT. |
| Rayner et al.30 | x | | | | | | | Greater % of patients in intervention arm had improved ACR (63 vs. 43%) and attained target A1c < 7% (50 vs. 31.6%). No statistically significant difference in hypoglycemia, lipid control, and BP. Lower proportion developed ESRD in intervention (13 vs. 28%). |
| Fogelfeld et al.31 | x | x | x | x | | | | Not all outcomes reported in the DM/CKD group. Lower fasting glucose (218 to 137 mg/dl), proteinuria (1.6 to 1.0 mg/mmol), SBP (143 to 125 mmHg), DBP (87 to 79 mmHg), and eGFR (55 to 53 ml/min/1.73 m²) after intervention. |
| Luciano Ede et al.32 | x | | | x | | | x | Not all outcomes reported in the DM/CKD group. Lower fasting glucose (218 to 137 mg/dl), proteinuria (1.6 to 1.0 mg/mmol), SBP (143 to 125 mmHg), DBP (87 to 79 mmHg), and eGFR (55 to 53 ml/min/1.73 m²) after intervention. |
| Glover et al.33 | x | x | x | x | | | | Higher proportion met target SBP (53 vs. 67%), A1c (20 vs. 51%), and total cholesterol (52 to 80% mg/mmol) after intervention; 7% died and 5% reached ESRD |
| Lipscombe et al.34 | | | | | x | x | | Chiropodist care protective against death, amputation in regression analysis. Percentage of patients with amputations decreased each year of program (9 to 2.9 amputations during last year). |
| Low et al.45 | x | x | | x | | | | 45.8 vs. 54.2% progressed to CKD stage 5 in case (i.e. diabetes–kidney clinic) compared with control group (45% lower hazard). Linear mixed models noted reduction in A1c, DBP, and ACR in cases. No difference in SBP and LDL between groups. |
| **Telemedicine**<br>Ishani et al.35 | x | x | x | x | | x | | Not all outcomes reported in CKD/DM. No difference in outcomes between intervention and control. |
| Joubert et al.36 | x | | | | | | | A1c declined significantly after intervention (6.85 to 6.46%) and mean CGM glucose (8.3 to 7.7 mmol/l). |
| Kepenekian et al.37 | x | | | | | | | Lower A1c (8.4 to 7.6%) after intervention as well as mean CGM glucose (9.9 to 8.9 mmol/l). No severe hypoglycemic events. |
| **Dialysis-based diabetes care program**<br>Prentice et al.38 | | | | | | | x | Significant reduction in number of wounds, improvement in grade of wounds. No significant improvement in staging of wound. Five new amputations after intervention. |
| McMurray and McDougall39 | | | | | | x | | No amputations in intervention group versus 5 lower extremity versus 2 finger amputations in controls. Fewer hospitalizations for DM, PVD, infections, and amputations in intervention group. When usual care switched to intervention, decrease in diabetes-related hospitalizations and amputations from the preceding year. |
| Table 2. (continued) |
|--------------------|
| **Glycemia** | **Cholesterol** | **BP** | **Renal** | **Retinopathy** | **Ulcers/amputation** | **CVD** | **Death** | **Results** |
| Neil et al.\(^{41}\) | x | | | | | | | No new foot ulcers. One developed a new toe ulcer (unclear if patient is in intervention or control group). |
| McMurray et al.\(^{40}\) | | x | x | | | | | A1c declined from 6.9% to 6.3% in intervention (no change in controls), no severe hypoglycemic events, no progression of neuropathic disease in intervention (progression in control), no amputations (5 lower extremity and 2 finger amputation in control), fewer diabetes/vascular-related hospitalizations (10 vs. 1 in control), and foot risk assessment scores remained unchanged (2.0 to 2.2) in intervention (worsened in controls; 2.7 vs. 3.3). Majority had screening eye exam. No change in mortality. |
| Cappy et al.\(^{42}\) | x | | | | | | | Mean glucose nonsignificantly declined (12.9 to 11.7 mmol/l). Mean A1c levels did not change significantly but three patients experienced improvement. |
| Marn Pernat et al.\(^{43}\) | | | | x | | | | Amputation rate pre-intervention 1.30 per 100 PY, post-intervention 1.07 per 100 PY (rate reduction of 17%, \(p = 0.0034\)). |

BP: blood pressure; CVD: cardiovascular disease; CKD: chronic kidney disease; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; A1c: hemoglobin A1c; BP: blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; SBP: systolic blood pressure; ACR: albumin to creatinine ratio; DBP: diastolic blood pressure; HD: hemodialysis; ESRD: end-stage renal disease; PY: person-years; RRT: renal replacement therapy; CGM: continuous glucose monitoring; PVD: peripheral vascular disease.
blood pressure. Studies were small and most often observational in design.19–23,44

Over the short term, programs were described to have small positive effects on glycemic control, blood pressure control, and kidney function. In one study where participants learned to self-manage and self-titrate their own blood pressure medications, there may have been beneficial effects on renal outcomes (i.e. the need for renal replacement therapy), amputation, blindness, and death.23

**Nurse-led care clinics**

Two small studies evaluated the effect of nurse-led care clinics on diabetes-related outcomes. At outpatient appointments, nurses adjusted participants’ cardioprotective (i.e. blood pressure and lipid-lowering agents) and glycemic medications, conducted diabetes-related screening (e.g. foot screening), and provided education, adherence, and self-management support. Clinic visits were offered up to twice per month.

Over the short term, nurse-led care was described to have beneficial effects on glycemia, blood pressure, lipid control, and kidney function. Their effect on other microvascular outcomes, macrovascular outcomes, or death was not described.24,25

**Interdisciplinary care clinics**

Interdisciplinary care clinics were the most frequent care strategy studied. These clinics brought health-care professionals together to provide diabetes-related care at a single outpatient visit. The majority of studies were observational, but included more participants than studies of other programs.26–34,45

At their appointments, participants had their cardioprotective and glycemic medications adjusted, were screened for diabetes-related complications, and were offered self-management support. Appointments were offered up to once per month, and in some cases, remotely between clinic visits (i.e. telephone support). In some studies, routine interdisciplinary team meetings were also held to discuss participant cases.

Interdisciplinary care may have had beneficial effects on glycemic, lipid, blood pressure control, and kidney function. Where studied, cardiovascular outcomes, end-stage kidney disease, amputations, and mortality may have been lower in participants who were part of interdisciplinary care clinics.

**Telemedicine**

Telemedicine strategies used telecommunications to deliver diabetes-related health services to patients (i.e. technology, telephone-based support).35–37

In two small studies, patients wore continuous glucose monitoring (CGM) devices, and blood sugars were sent remotely to care providers for glycemic medication adjustment. Another randomized controlled study offered remote, interprofessional care to patients via a telemedicine device.

Short-term improvements in glycemic control (i.e. 3 months) was reported in CGM studies. Remote interprofessional care did not appear to reduce the risk of microvascular outcomes, macrovascular outcomes, or death in patients with CKD and diabetes.

**Dialysis-based diabetes care**

Dialysis-based diabetes care strategies offered care to patients during hemodialysis sessions. Studies of these programs were small, observational, and often did not involve a control group.38–43

The majority were foot care programs where patients received education and had their feet examined while dialyzing. One study offered multifactorial diabetes care to patients in the dialysis unit (i.e. glycemic control, self-management support, foot care).40 Support was offered up to weekly, by hemodialysis nurses and in-unit diabetes case managers.

Programs may have had beneficial effects on glycemic control, ulcers, amputations, and death.

**Discussion**

Twenty-five to 50% of patients with diabetes live with CKD.8 Where the prevalence of multimorbidity will only continue to increase,1 it is important to evaluate new strategies to provide these complex individuals with patient-centered health care.

We conducted a comprehensive scoping review of the medical and grey literature to systematically identify and describe nonconventional diabetes-related care strategies and their effects on diabetes-related outcomes in adults with diabetes and CKD. We found that unique self-management and education programs, telemedicine, dialysis-based diabetes care, nurse-led care clinics, interdisciplinary care clinics, and community-based care programs have been evaluated in some patients with diabetes and stages 2–4 CKD. Care programs were most often developed by study investigators and were in some cases time and resource-intensive (e.g. offered care up to once weekly, used telemedicine technology).

Programs were described to have beneficial effects on glycemic, lipid, blood pressure control, and kidney function. However, studies were limited in their design (observational, lack of control), involved a small number of participants (typically < 100), and were short in duration. Where RCTs of programs were conducted, community-based diabetes care, self-management education programs, and interdisciplinary care clinics had reported benefits.

Based upon our review, we might suggest that prior to developing, implementing, or continuing these programs
(i.e. in centers that may already have access to nonconventional strategies), it might be beneficial to study these strategies as part of large RCTs. Given the complexity of some programs, it would also be important to understand their feasibility on a larger scale because of their resource and time requirements. Finally, given low participant numbers and often high dropout rates in some studies, consideration should be given to involving patients in program design. This might ensure that interventions address patient values and their cultural and psychosocial needs. This may better promote patient adherence to interventions.

**Strengths and limitations**

We conducted a comprehensive review and abstracted study data using standardized processes and structured tools. We screened and abstracted citations in duplicate. We summarized the characteristics of studies and interventions, and we noted any beneficial effects on diabetes-related outcomes.

There are limitations to discuss. Our review was a scoping review rather than a systematic review. As such, we included all levels of evidence (i.e. did not restrict to RCTs). Although we commented upon some of the limitations of included studies, we did not formally evaluate their quality. We also excluded non-English studies and we were lenient in our definition of CKD. CKD is typically defined by an eGFR < 60 ml/min/1.73 m² or microalbuminuria lasting >3 months. Some studies did not report these definitions per se, and as such, some patients may have been misclassified with this condition.

Although we used broad search terms, due to the nature of our research question, we may not have identified all nonconventional strategies. We used the EPOC taxonomy to classify care programs but recognize that some programs had overlapping features (i.e. nurse-led clinics also offered self-management strategies). We did summarize study characteristics and outcomes, but were unable to draw conclusions about the most effective care strategies for adult patients with diabetes and CKD.

**Conclusions**

Small, frequently observational studies, have described that nontraditional diabetes care strategies might potentially be effective for patients with diabetes and CKD. We suggest that before developing and studying new ways of caring for patients with multimorbidity, patients should be included in program development, they should be studied in a randomized-controlled fashion, and the feasibility and health economic benefit of these programs should be explored in a real-life setting.

**Acknowledgment**

The authors would like to thank Brad Dishan (BD) for developing the search strategy and conducting the literature search.

**Declaration of conflicting interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Unrelated to this work, Kristin Clemens received a Diabetes Canada Junior Investigator Award supported by AstraZeneca in 2017. She has also received travel and conference support from Merck. Unrelated to this work, Sonja Reichert has participated in an investigator-initiated research grant from Sanofi. She has also received personal fees for presentations and participation in advisory boards from Sanofi, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Servier, Janssen, Eli Lilly, Merck, and Abbott. There are no other conflicts of interest to disclose.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Canadian Institutes of Health Research/Strategy for Patient Oriented Research through a Patient Oriented Research Collaboration Grant. The work of Vinusha Kalatharan was supported by a Canadian Institutes of Health Research Doctoral Scholarship and a Doctoral Scholarship from the KRESSENT Program.

**ORCID iD**

Kristin K Clemens https://orcid.org/0000-0001-9636-5597

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Piette JD and Kerr EA. The impact of comorbid chronic conditions on diabetes care. *Diabetes Care* 2006; 29(3): 725–731.
2. Wolff JL, Starfield B and Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. *Arch Intern Med* 2002; 162(20): 2269–2276.
3. Maddigan SL, Feeny DH and Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. *Qual Life Res* 2005; 14(5): 1311–1320.
4. Hodge M, McArthur E, Garg AX, et al. Hypoglycemia incidence in older adults by estimated GFR. *Am J Kidney Dis* 2017; 70(1): 59–68.
5. Pugliese G, Solini A, Bonora E, et al. Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italy. *Cardiovasc Diabetol* 2014; 13: 59.
6. System USRD. 2014 USRDS Annual Data Report, 2014, https://www.usrds.org/2014/view/ (accessed 15 December 2017).
7. McFarlane PA, Tobe SW and Culleton B. Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines. *Can J Cardiol* 2007; 23(7): 585–590.
8. Lloyd A and Komenda P. Optimizing care for Canadians with diabetic nephropathy in 2015. *Can J Diabetes* 2015; 39(3): 221–228.
9. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and Explanation. *Ann Intern Med* 2018; 169(7): 467–473.
10. Arksey H and O’Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005; 8(1): 19–32.
11. Colquhoun HL, Levac D, O’Brien KK, et al. Scoping reviews: time for clarity in definition, methods, and reporting. *J Clin Epidemio* 2014; 67(12): 1291–1294.
12. Tobe SW, Pylypchuk G, Wentworth J, et al. Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial. *CMAJ* 2006; 174(9): 1267–1271.
13. Senior PA, MacNair L and Jindal K. Delivery of multifactorial interventions by nurse and dietitian teams in a community setting to prevent diabetic complications: a quality-improvement report. *Am J Kidney Dis* 2008; 51(3): 425–434.
14. Tan J, Manley P, Gamble G, et al. Long-term effectiveness of a community-based model of care in Māori and Pacific patients with type 2 diabetes and chronic kidney disease: a 4-year follow up of the DElay Future End Stage Nephropathy due to Diabetes (DEFEND) study. *Intern Med J* 2015; 45(8): 843–849.
15. Jiamjariyapon T, Ingsathit A, Pongpirul K, et al. Effectiveness of Integrated Care on Delaying Progression of stage 3-4 Chronic Kidney Disease in Rural Communities of Thailand (ESCORT study): a cluster randomized controlled trial. *BMC Nephrol* 2017; 18(1): 83. Epub ahead of print 2017. DOI: 10.1186/s12882-016-0414-4.
16. Tan J, McCready F, Noovao F, et al. Intensification of blood pressure treatment in Pasifika people with type 2 diabetes and renal disease: a cohort study in primary care. *NZ Med J* 2014; 127(1404): 17–26.
17. Walker RC, Marshall MR and Polaschek NR. A prospective clinical trial of specialist renal nursing in the primary care setting to prevent progression of chronic kidney: a quality improvement report. *BMC Fam Pract* 2014; 15: 155.
18. Thomas N, Gallagher H and Jain N. A quality improvement project to improve the effectiveness and patient-centredness of management of people with mild-to-moderate kidney disease in primary care. *BMJ Qual Improv Reports* 2014; 3(1): 1–5. Epub ahead of print 2014. DOI: 10.1136/bmjquality.u20137.w825.
19. Sevick MA, Korytkowski M, Stone RA, et al. Biophysiologic outcomes of the Enhancing Adherence in Type 2 Diabetes (ENHANCE) Trial. *J Acad Nutr Diet* 2012; 112(8): 1147–1157.
20. Pagels AA, Hylander B and Alvarsson M. A multi-dimensional support programme for patients with diabetic kidney disease. *J Ren Care* 2015; 41(3): 187–194.
21. Thomas N and Bryar R. An evaluation of a self-management package for people with diabetes at risk of chronic kidney disease. *Prim Health Care Res Dev* 2013; 14(3): 270–280.
22. Kazawa K, Takeshita Y, Yorioka N, et al. Efficacy of a disease management program focused on acquisition of self-management skills in pre-dialysis patients with diabetic nephropathy: 24 months follow-up. *J Nephrol* 2015; 28(3): 329–338.
23. Trocha AK, Schmidtke C, Didurse U, et al. Effects of intensified antihypertensive treatment in diabetic nephropathy: mortality and morbidity results of a prospective controlled 10-year study. *J Hypertens* 1999; 17(10): 1497–1503.
24. Van Zuilen AD, Wetzels JF, Blankestijn PJ, et al. Rationale and design of the MASTERPLAN study: multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. *J Nephrol* 2005; 18(1): 30–34.
25. Woodward A, Wallymahmed M, Wilding J, et al. Successful cardiovascular risk reduction in type 2 diabetes by nurse-led care using an open clinical algorithm. *Diabet Med* 2006; 23(7): 780–787.
26. Garcia-Garcia G, Martinez-Castellanos Y, Renoirte-Lopez K, et al. Multidisciplinary care for poor patients with chronic kidney disease in Mexico. *Kidney Int Suppl* 2013; 3(2): 178–183.
27. Leung WYS, So WY, Tong PCY, et al. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. *Am J Med* 2005; 118(12): 1414.
28. Hitomi M, Sato T and Moriya T. The predialysis multidisciplinary individual team approach (MTA) improved self-management and prognosis for patients with diabetic nephropathy (DN) on hemodialysis (HD). *Diabetes* 2017; 66: A181.
29. Bayliss EA, Bhardwaja B, Ross C, et al. Multidisciplinary team care may slow the rate of decline in renal function. *Clin J Am Soc Nephrol* 2011; 6(4): 704–710.
30. Rayner HC, Hollingsworth L, Higgins R, et al. Systematic kidney disease management in a population with diabetes mellitus: turning the tide of kidney failure. *BMJ Qual Saf* 2011; 20(10): 903–910.
31. Fogelfeld L, Hart P, Miernik J, et al. Combined diabetes-renal multifactorial intervention in patients with advanced diabetic nephropathy: proof-of-concept. *J Diabetes Complications* 2017; 31(3): 624–630.
32. Luciano Ede P, Luconi PS, Sesso RC, et al. Prospective study of 2151 patients with chronic kidney disease under conservative treatment with multidisciplinary care in the Vale do Paraíba, SP. *J Bras Nefrol* 2012; 34(3): 226–234.
33. Glover R, Thangavelu A and Kumwenda M. Examining the effectiveness of a diabetic nephropathy clinic. *J Ren Nurs* 2012; 4(5): 228–230.
34. Lipscombe J, Jassal SV, Bailey S, et al. Chiropody may prevent amputations in diabetic patients on peritoneal dialysis. *Perit Dial Int* 2003; 23(3): 255–259.
35. Ishani A, Christopher J, Palmer D, et al. Telehealth by an Interprofessional Team in Patients with CKD: a Randomized Controlled Trial. *Am J Kidney Dis* 2016; 68(1): 41–49.
36. Joubert M, Fourmy C, Henri P, et al. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. *Diabetes Res Clin Pract* 2015; 107(3): 348–354.
37. Kepenekian L, Smagala A, Meyer L, et al. Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study. Clin Nephrol 2014; 82(4): 240–246.
38. Prentice D, Ritchie L, Crandall J, et al. Implementation of a diabetic foot management best practice guideline (BPG) in hemodialysis units. CANNT J 2009; 19(4): 20–24.
39. McMurray SD and McDougall K. Improving diabetes foot care in the dialysis facility. Nephrol News Issues 2003; 17(10): 57, 60–61, 65–66.
40. McMurray SD, Johnson G, Davis S, et al. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002; 40(3): 566–575.
41. Neil JA, Knuckey CJ and Tanenberg RJ. Prevention of foot ulcers in patients with diabetes and end stage renal disease. Nephrol Nurs J 2003; 30(1): 39–43.
42. Cappy CS, Jablonka J and Schroeder ET. The effects of exercise during hemodialysis on physical performance and nutrition assessment. J Ren Nutr 1999; 9(2): 63–70.
43. Marn Pernat A, Peršič V, Usvyat L, et al. Implementation of routine foot check in patients with diabetes on hemodialysis: associations with outcomes. BMJ Open Diabetes Res Care 2016; 4(1): e000158.
44. Williams A, Manias E, Walker R, et al. A multifactorial intervention to improve blood pressure control in coexisting diabetes and kidney disease: a feasibility randomized controlled trial. J Adv Nurs 2012; 68(11): 2515–2525.
45. Low S, Lim SC, Wang J, et al. Long-term outcomes of patients with type 2 diabetes attending a multidisciplinary diabetes kidney disease clinic. J Diabetes 2018; 10(7): 572–580. Epub ahead of print 28 December 2017. DOI: 10.1111/1753-0407.12626.
46. Norwegian Knowledge Centre for Health Services. Effective Practice and Organisation of Care (EPOC) – the EPOC taxonomy of health systems interventions, https://epoc.cochrane.org/epoc-taxonomy (2015, accessed 1 December 2018).
47. Donald M, Kahlon BK, Beanlands H, et al. Self-management interventions for adults with chronic kidney disease: a scoping review. BMJ Open 2018; 8(3): e019814.
48. Peters MDJ, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc 2015; 13(3): 141–146.